Iqvia (IQV) Getting Somewhat Positive Press Coverage, Analysis Finds

Media headlines about Iqvia (NYSE:IQV) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iqvia earned a news sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 45.9525593002802 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

Iqvia (NYSE IQV) traded down $0.18 during mid-day trading on Thursday, reaching $100.14. The company’s stock had a trading volume of 1,288,718 shares, compared to its average volume of 1,490,293. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia has a 52 week low of $74.73 and a 52 week high of $110.67. The stock has a market cap of $21,060.86, a P/E ratio of 23.12, a PEG ratio of 1.61 and a beta of 0.61.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the previous year, the business earned $1.00 EPS. Iqvia’s revenue for the quarter was up 77.6% compared to the same quarter last year. equities research analysts anticipate that Iqvia will post 4.62 EPS for the current fiscal year.

A number of research firms have recently commented on IQV. TheStreet upgraded Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. Mitsubishi UFJ Financial Group began coverage on Iqvia in a report on Friday, December 15th. They set a “neutral” rating and a $112.00 target price on the stock. KeyCorp reiterated a “buy” rating and set a $100.00 target price on shares of Iqvia in a report on Sunday, September 24th. Robert W. Baird reiterated a “hold” rating and set a $98.00 target price on shares of Iqvia in a report on Monday, October 9th. Finally, Zacks Investment Research downgraded Iqvia from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Iqvia currently has a consensus rating of “Buy” and a consensus price target of $106.94.

In other news, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction that occurred on Wednesday, September 27th. The stock was sold at an average price of $94.52, for a total value of $945,200.00. Following the completion of the transaction, the insider now owns 27,340 shares in the company, valued at approximately $2,584,176.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of Iqvia stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total value of $764,776,314.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,852,638 shares of company stock worth $903,028,661 over the last 90 days. 6.40% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Iqvia (IQV) Getting Somewhat Positive Press Coverage, Analysis Finds” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit